1. Home
  2. AGAE vs PMN Comparison

AGAE vs PMN Comparison

Compare AGAE & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGAE
  • PMN
  • Stock Information
  • Founded
  • AGAE 2017
  • PMN 2004
  • Country
  • AGAE United States
  • PMN Canada
  • Employees
  • AGAE N/A
  • PMN N/A
  • Industry
  • AGAE Cable & Other Pay Television Services
  • PMN Pharmaceuticals and Biotechnology
  • Sector
  • AGAE Telecommunications
  • PMN Health Care
  • Exchange
  • AGAE Nasdaq
  • PMN Nasdaq
  • Market Cap
  • AGAE 50.8M
  • PMN 29.8M
  • IPO Year
  • AGAE N/A
  • PMN N/A
  • Fundamental
  • Price
  • AGAE $1.00
  • PMN $0.94
  • Analyst Decision
  • AGAE
  • PMN
  • Analyst Count
  • AGAE 0
  • PMN 0
  • Target Price
  • AGAE N/A
  • PMN N/A
  • AVG Volume (30 Days)
  • AGAE 24.3K
  • PMN 43.3K
  • Earning Date
  • AGAE 03-26-2025
  • PMN 03-31-2025
  • Dividend Yield
  • AGAE N/A
  • PMN N/A
  • EPS Growth
  • AGAE N/A
  • PMN N/A
  • EPS
  • AGAE N/A
  • PMN N/A
  • Revenue
  • AGAE $9,256,023.00
  • PMN N/A
  • Revenue This Year
  • AGAE N/A
  • PMN N/A
  • Revenue Next Year
  • AGAE N/A
  • PMN N/A
  • P/E Ratio
  • AGAE N/A
  • PMN N/A
  • Revenue Growth
  • AGAE 36.15
  • PMN N/A
  • 52 Week Low
  • AGAE $0.61
  • PMN $0.87
  • 52 Week High
  • AGAE $1.57
  • PMN $2.61
  • Technical
  • Relative Strength Index (RSI)
  • AGAE 60.22
  • PMN 56.16
  • Support Level
  • AGAE $1.03
  • PMN $0.90
  • Resistance Level
  • AGAE $1.19
  • PMN $0.95
  • Average True Range (ATR)
  • AGAE 0.06
  • PMN 0.06
  • MACD
  • AGAE 0.01
  • PMN 0.01
  • Stochastic Oscillator
  • AGAE 54.55
  • PMN 67.79

About AGAE Allied Gaming & Entertainment Inc.

Allied Gaming & Entertainment Inc is an experiential entertainment company focused on providing a growing world of gamers with various experiences through renowned assets, products, and services.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Share on Social Networks: